What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA) , Micron Technology (MU) , Canada Goose (GOOS) , Moderna (MRNA) , Shopify (SHOP) , Block (SQ) , Teladoc Health (TDOC) , Zoom Video Communications (ZM) , Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ) .

How do I buy shares of Trillium Therapeutics?

Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TRIL Stock Alerts

Compare

Today's Range: N/A
50-Day Range: C$23.33
▼
C$23.33
52-Week Range: N/A

Volume: 60,423 shs
Average Volume: 166,586 shs
Market Capitalization: C$2.45 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Trillium Therapeutics alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Trillium Therapeutics Stock (TSE:TRIL)

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

TRIL Stock News Headlines

April 11, 2024 | seekingalpha.com

SYRE Spyre Therapeutics, Inc.

February 22, 2024 | benzinga.com

Viking Therapeutics Stock (NASDAQ:VKTX), Analyst Ratings, Price Targets, Predictions

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 21, 2024 | health.usnews.com

Blue Cross & Blue Shield of Rhode Island Insurance Company Medicare Advantage Plans with Part D

April 7, 2023 | marketwatch.com

2023-2030 Bromodomain Containing Protein 2 Market Size Detailed Report with Sales and Revenue Analysis | Research by Absolute Reports

March 23, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

March 13, 2023 | finance.yahoo.com

Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology

March 13, 2023 | reuters.com

Factbox: Pfizer snaps up Seagen for $43 bln as drugmaker extends buying spree

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 24, 2023 | benzinga.com

Allogene Therapeutics Stock (NASDAQ:ALLO), Quotes and News Summary

February 23, 2023 | finance.yahoo.com

Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer

February 6, 2023 | markets.businessinsider.com

Viridian Therapeutics Names Scott Myers CEO, Succeeding Jonathan Violin

October 26, 2022 | finance.yahoo.com

Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety

August 5, 2022 | finance.yahoo.com

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ

July 29, 2022 | ca.finance.yahoo.com

Leukemia Therapeutics Global Market Report 2022

July 18, 2022 | thestreet.com

Trillium Therapeutics Inc. News

June 10, 2022 | finance.yahoo.com

Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers

May 10, 2022 | chron.com

Pfizer Pays $11.6 Billion for Drug-Maker in Its Biggest Deal Since 2016

May 10, 2022 | finanznachrichten.de

Bloom Burton & Co. Inc.: Three Finalists Announced for the 2022 Bloom Burton Award

May 10, 2022 | stockhouse.com

Three Finalists Announced for the 2022 Bloom Burton Award

May 10, 2022 | yahoo.com

Pfizer to buy migraine drugmaker Biohaven in $11.6-billion deal

January 26, 2022 | finance.yahoo.com

GenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

December 16, 2021 | au.finance.yahoo.com

CD47 Targeting Global Therapeutics Market 2021-2035, by Target Disease Indication, Type of Molecule Key Players and Key Geographical Regions

October 28, 2021 | finance.yahoo.com

Trillium Therapeutics Receives Final Court Order Approving Arrangement

October 26, 2021 | theglobeandmail.com

Shareholders of cancer-drug developer Trillium Therapeutics approve takeover by Pfizer Inc.

October 26, 2021 | finance.yahoo.com

Trillium Securityholders Approve Acquisition by Pfizer

October 13, 2021 | law360.com

Pfizer Gives Gov't More Time To Study $2.3B Trillium Deal

See More Headlines

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:TRIL
Previous Symbol: TSE:SSS
CUSIP: N/A
CIK: N/A
Web: www.trilliumtherapeutics.com
Phone: +1-416-5950627
Fax: N/A
Employees: 33
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 12.04
Quick Ratio: 11.54

Sales & Book Value

Annual Sales: C$43,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 9.77
Book Value: C$2.17 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 104,995,000
Free Float: N/A
Market Cap: C$2.45 billion
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jan Skvarka (Age 54)
Pres, CEO & Director
Comp: $812.5k
Mr. James T. Parsons C.A. (Age 56)
C.P.A., MAcc, CPA-CA, Chief Financial Officer
Comp: $543.38k
Dr. Robert Uger (Age 50)
Chief Scientific Officer
Comp: $595.73k
Dr. Penka Petrova (Age 53)
Chief Devel. Officer
Comp: $553.53k
Dr. Ingmar Bruns M.D. (Age 46)
Ph.D., Chief Medical Officer
Comp: $230k
Benjamin Looker
Gen. Counsel
Dr. Rosemary Harrison (Age 38)
Sr. VP of Corp. Devel. & Strategy
Dr. Michael G. Hill
Head of Calgary Site
Ms. Kathleen Large (Age 61)
Sr. VP - Clinical Operations

Key Competitors

View All Competitors

TRIL Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Trillium Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Canada Goose (GOOS), Moderna (MRNA), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Zoom Video Communications (ZM), Advanced Micro Devices (AMD) and Canadian Natural Resources (CNQ).
How do I buy shares of Trillium Therapeutics?: Shares of TRIL stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:TRIL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

About Trillium Therapeutics Stock (TSE:TRIL)

TRIL Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TRIL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info